Earnings call transcript: Eurazeo’s Q1 2026 Shows Strong Fundraising, Stock Rises

Eurazeo delivered a strong Q1 2026 update, with fundraising up 11% year over year to €1.1 billion and assets under management up 7% to €39 billion; private debt fundraising nearly doubled to more than €850 million. Management also reiterated a path for performance fees to reach about 10% of third-party management revenues by end-2027 and confirmed ongoing share buybacks at roughly 1% of capital per quarter. Shares rose 2.5% on the release, though the stock still trades down 9.6% year to date and 27% over the past year.

Analysis

The core signal is not the top-line fundraise beat; it is the improving conversion of product momentum into a self-reinforcing fee base. When a manager is simultaneously growing third-party AUM faster than group AUM and reducing balance-sheet dependence, the business mix becomes less capital intensive and more visible to public-market investors — but only after a lag, because performance fees are still a minor contributor. That lag is the opportunity: the market is still discounting this as a plain-vanilla asset gatherer, while the next 4-6 quarters should show operating leverage from higher fee-paying AUM, less drag from balance-sheet commitments, and a better mix toward private debt and evergreen products.

The second-order winner is private credit distribution, not just Eurazeo itself. A faster ramp in direct lending and wealth-solution channels should pressure smaller European private market platforms that lack differentiated origination or retail packaging capability; those firms will see slower fundraising and weaker pricing power with distributors. The balance-sheet rotation also matters: redeploying toward third-party products can support fees but may cap near-term NAV growth, so the equity story shifts from ‘book value compounding’ to ‘recurring fee annuity with call option on performance fees.’

The contrarian risk is that investors may be overestimating near-term Evergreen economics. Retail wrappers usually need inventory, distributor onboarding, and education before flows inflect, so the first half of 2026 likely matters more for pipeline proof than revenue contribution. If macro volatility or market drawdowns hit private-equity marks, the implied performance-fee ramp can slip by 2-3 quarters, which would compress the valuation case even if fundraising remains solid.

Key Decisions for Investors

• Long EZU/European asset-manager basket vs short European financials with balance-sheet-heavy models over 3-6 months; thesis is mix shift and fee leverage outperform low-growth capital intensity.
• Buy Eurazeo on weakness after any post-rally consolidation; target 15-20% upside over 6-12 months as fee-paying AUM growth and performance-fee realization close the valuation gap.
• Pair trade: long Eurazeo vs short a listed European private-markets peer with weaker fundraising momentum; look for relative outperformance if private debt and wealth-channel traction persists into H2 2026.
• Sell downside via cash-secured puts or put spreads into the next 1-2 quarters if implied volatility stays elevated; downside is cushioned by buybacks, while the catalyst path is gradual rather than binary.
• Avoid chasing in the near term if macro risk assets roll over; the main failure mode is delayed Evergreen monetization and mark-to-market pressure, which could pause multiple expansion for 1-2 quarters.